In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping performance of the INNO-LiPA HPV Genotyping Extra II (INNO-LiPA) within the VALGENT-3 framework. VALGENT is designed to assess the analytical and clinical performance of HPV tests with genotyping capacity. The VALGENT-3 panel comprised 1300 consecutive cervical cell specimens enriched with 300 samples with abnormal cytology obtained from women attending the Slovenian cervical cancer screening programme. The INNO-LiPA allows type-specific detection of 32 HPV types; however, for the clinical accuracy assessment, we considered it as high-risk (hr)HPV positive when at least one of the following HPV types was present: HPV16, HPV18, HPV31, HPV33, HPV35,...
<p>The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an op...
<p>As the demand for human papillomavirus (HPV)-related cervical screening increases, emerging...
<p><b>BACKGROUND: </b>Cervical cancer screening programs are switching from cytolo...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
<p>In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyp...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
Human papillomavirus (HPV) testing is increasingly being incorporated into cervical cancer screening...
Background: The HPV genotyping line probe assay INNO-LiPA EXTRA allows the detection of a wider spec...
BACKGROUND: Accurate HPV detection and genotyping tests are useful for management of women with HPV...
Background: Cervical cancer screening programs are switching from cytology-based screening to high-r...
The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an opportunity...
Background: The VALidation of HPV GENoyping Tests (VALGENT) framework is designed for comparison and...
In 2012, VALidation of human papillomavirus (HPV) GENotyping Tests (VALGENT) was initiated to provid...
Only clinically validated human papillomavirus (HPV) tests should be used in cervical cancer screeni...
<p>The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an op...
<p>As the demand for human papillomavirus (HPV)-related cervical screening increases, emerging...
<p><b>BACKGROUND: </b>Cervical cancer screening programs are switching from cytolo...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
<p>In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyp...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
Human papillomavirus (HPV) testing is increasingly being incorporated into cervical cancer screening...
Background: The HPV genotyping line probe assay INNO-LiPA EXTRA allows the detection of a wider spec...
BACKGROUND: Accurate HPV detection and genotyping tests are useful for management of women with HPV...
Background: Cervical cancer screening programs are switching from cytology-based screening to high-r...
The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an opportunity...
Background: The VALidation of HPV GENoyping Tests (VALGENT) framework is designed for comparison and...
In 2012, VALidation of human papillomavirus (HPV) GENotyping Tests (VALGENT) was initiated to provid...
Only clinically validated human papillomavirus (HPV) tests should be used in cervical cancer screeni...
<p>The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an op...
<p>As the demand for human papillomavirus (HPV)-related cervical screening increases, emerging...
<p><b>BACKGROUND: </b>Cervical cancer screening programs are switching from cytolo...